Company Overview - MeiraGTx Holdings PLC (MGTX) shares increased by 12.4% to $9.26 in the last trading session, with a higher-than-average trading volume [1] - The stock has gained 1.9% over the past four weeks [1] Clinical Programs - The price rise is attributed to growing investor confidence in the company's late-stage clinical programs targeting Parkinson's disease, radiation-induced xerostomia, and AIPL1-associated retinal dystrophy [2] - These programs utilize targeted local delivery of small doses of genetic medicines to address severe unmet medical needs [2] Financial Expectations - The company is expected to report a quarterly loss of $0.51 per share, reflecting a year-over-year increase of 5.6% [3] - Projected revenues are $4.43 million, down 59.4% from the same quarter last year [3] Earnings Estimates - The consensus EPS estimate for MeiraGTx has remained unchanged over the last 30 days [4] - A stock's price typically does not continue to rise without trends in earnings estimate revisions, indicating the need to monitor MGTX for potential future strength [4] Industry Context - MeiraGTx is part of the Zacks Medical - Biomedical and Genetics industry, which includes Urogen Pharma (URGN) [5] - Urogen Pharma's stock closed 0.8% higher at $18.14, with a 0% return over the past month [5] - Urogen Pharma's consensus EPS estimate has also remained unchanged at -$0.7, representing a 27.3% decline from the previous year [6]